A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.

Sibeprenlimab is under clinical development by Visterra and currently in Phase III for IgA Nephropathy (Berger's Disease).

Quisovalimab is under clinical development by Avalo Therapeutics and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR ...

VMT-01 is under clinical development by Perspective Therapeutics and currently in Phase II for Metastatic Melanoma.

Pridopidine hydrochloride is under clinical development by Prilenia Therapeutics Development and currently in Phase III for Huntington Disease.

Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome.

Hydrocodone IR is under clinical development by Elysium Therapeutics and currently in Phase I for Opium (Opioid) Addiction.

GH-002 is under clinical development by GH Research and currently in Phase I for Treatment Resistant Depression.

GPN Vaccines, formerly GPN Vaccines, is a clinical-stage company focused on creating vaccines that offer robust protection against bacterial pathogens. It develops vaccines to protect adults and ...